Amgen plans to conduct VESALIUS-CV, a multinational clinical outcomes study including at least 13,000 patients that will explore the potential of Repatha®(evolocumab) for the prevention of a first cardiovascular (CV) event in patients at high cardiovascular risk without a prior heart attack or stroke.1 The study will be the first to investigate long-term outcomes in this population with Repatha for a minimum of four years.1 The safety and efficacy of Repatha has not been established for this use. Named after the legendary scientist Andreas Vesalius, who was one of the first to accurately depict the anatomy and function of the heart,2 this study is an important addition to PROFICIO (Program to Reduce LDL-C and cardiovascular Outcomes Following Inhibition of PCSK9 In different pOpulations), the growing clinical program for Repatha.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.